The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells
Pauline Estupina et al, 2017, Oncotarget CrossRef
Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR
Sarah E. Gill et al, 2017, Oncotarget CrossRef
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
Houcine Bougherara et al, 2017, Oncotarget CrossRef
Anti-mullerian hormone receptor type II as a Potential Target for Antineoplastic Therapy
A. Ya. Rak et al, 2019, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef
Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II
Cagri Sakalar et al, 2015, Journal of Immunology Research CrossRef
Interaction Study of Different Forms of Human Recombinant Anti-Mullerian Hormone with a Chimeric Analogue of the AMH Type II Receptor
A. Ya. Rak et al, 2021, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef
Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
Suparna Mazumder et al, 2020, Oncotarget CrossRef
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation
Mélissa Prat et al, 2021, Cancers CrossRef
The role of anti-Mullerian hormone in the context of modern pathogenetic approaches to the treatment of endometriosis (literature review)
N. A. Buralkina et al, 2023, Meditsinskiy sovet = Medical Council CrossRef
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer
Jean-Marc Barret et al, 2021, Biology CrossRef